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Background: There is an ongoing debate about the appropriate spirometric criterion for airway 
obstruction to detect COPD. Furthermore, the association of different criteria with comorbidity 
prevalence and inflammatory biomarkers in advanced age is unclear.
Materials and methods: Spirometry was performed in a population-based study (n=2,256) 
covering an age range of 41–90 years. COPD was spirometrically determined either by a fixed 
ratio (FR) of ,0.7 for forced expiratory volume in 1 second (FEV
1
)/forced vital capacity (FVC) 
or by FEV
1
/FVC below the lower limit of normal (LLN). Comorbidity prevalences and circu-
lating biomarker levels (C-reactive protein [CRP], interleukin [IL]-6) were compared between 
subjects with or without COPD by the two criteria using logistic and multiple regression models, 
adjusting for sex and age.
Results: The prevalence of spirometrically defined COPD by FR increased with age from 
10% in subjects aged ,65 years to 26% in subjects aged $75 years. For LLN-defined COPD, 
it remained below 10% for all age groups. Overall, COPD diagnosis was not associated with 
specific comorbidities, except for a lower prevalence of obesity in both FR- and LLN-defined 
cases. Both CRP and IL-6 tended to be higher in cases by both criteria.
Conclusion: In a population-based cohort of adults up to the age of 90 years, the prevalence 
of spirometrically defined COPD was higher for the FR criterion than for the LLN criterion. 
This difference increased with age. Neither prevalences of common comorbidities nor levels 
of the biomarkers, CRP or IL-6, were conclusively associated with the selection of the COPD 
criterion. Results have to be considered in light of the predominantly mild cases of airway 
obstruction in the examined study population.
Keywords: chronic obstructive pulmonary disease, spirometry, prevalence, comorbidity, 
biomarkers
Background
According to current recommendations, a clinical diagnosis of COPD is primarily 
based on the detection of airflow obstruction in spirometric measures.1,2 However, 
the spirometric criteria defining airflow obstruction in COPD are still subject to lively 
debate.3,4 The Global Initiative for Chronic Obstructive Lung Disease recommends the use 
of a fixed ratio (FR) of 0.7 for postbronchodilator forced expiratory volume in 1 second 
(FEV
1
)/forced vital capacity (FVC) to confirm the diagnosis.1 This approach has been 
criticized as arbitrary and argued to particularly overestimate prevalences in advanced 
age.5 Alternatively, the use of the fifth percentile of the predicted value (lower limit of 
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normal, LLN) for FEV
1
/FVC has been proposed by respira-
tory societies, eg, the American Thoracic Society and Euro-
pean Respiratory Society.6,7 It has been shown that the two 
COPD definitions lead to deviating prevalences.8 In addition, 
data and subjects in advanced age beyond 75 years are often 
underrepresented in the studied population-based samples.
Besides airflow obstruction, COPD is accompanied 
by a variety of systemic impairments.9 Comorbidities of 
COPD include cardiovascular disease, diabetes, depres-
sion, and cancer,10 and it has been reported that COPD may 
accelerate the progression of some of these comorbidities.9 
Moreover, COPD is characterized by low-grade systemic 
inflammation.11 Different biomarkers such as C-reactive 
protein (CRP)12 and interleukin (IL)-613 have been associ-
ated with a poor prognosis in COPD participants. Celli et al14 
showed that using a whole panel of inflammatory biomarkers 
(eg, CRP, IL-6, IL-8, and fibrinogen) improved the clinical 
prediction of mortality in COPD participants. Still, in how 
far circulating biomarker levels are affected by spirometric 
criteria is less investigated.
The aim of this investigation was 1) to quantify the impact 
of disease definition by different spirometric criteria (FR vs 
LLN) on COPD prevalence in a population-based sample and 
2) to evaluate the association of FR vs LLN criteria with comor-
bidity prevalences and selected inflammatory biomarkers.
Materials and methods
study participants
Within a population-based cohort from the Augsburg region 
(KORA, Cooperative Health Research in the Augsburg 
Region, Germany),15 two follow-up studies, KORA-F416 and 
KORA-Age,17 were launched from the MONICA/KORA 
surveys S1–S4. The KORA-F4 and KORA-Age studies were 
approved by the ethics committee of the Bavarian Medical 
Association, and written informed consent was obtained from 
all participants. Details of the KORA platform and surveys 
have been described earlier.15,18 Briefly, spirometry was 
performed in 1,321 subjects aged 41–63 years in KORA-F4 
(2006–2008) and in 935 subjects aged 65–90 years in KORA-
Age (2009). Measurement conditions for spirometry and the 
examiners were the same in both studies. Standing height 
and weight were measured with subjects wearing only light 
clothes and no shoes.
spirometry
Details on spirometric measurements have been reported 
earlier.16 In short, standard spirometry without bronchodi-
lation was performed in line with the American Thoracic 
Society/European Respiratory Society recommendations in an 
upright sitting position, while subjects were wearing nose clips 
using a pneumotachograph-type spirometer (MasterScope PC; 
CareFusion, Höchberg, Germany). The participants performed 
at least three spirometric maneuvers in order to obtain a 
minimum of two acceptable and reproducible values. Subjects 
were classified as having COPD if FEV
1
/FVC was ,0.7 for 
the FR criterion and if FEV
1
/FVC was , LLN for the LLN 





/FVC were used.19 The severity of 
COPD was graded according to the stages of disease based on 
FEV
1
 results into categories as defined by the Global Initiative 
for Chronic Obstructive Lung Disease.1
Comorbidities and biomarkers
Self-reported information on myocardial infarction (MI), 
stroke, cancer, diabetes, inflammatory joint disease/
rheumatic disease, gastrointestinal disease (GID), and COPD/
chronic bronchitis diagnosis was collected in standardized 
interviews, which were partly performed via telephone and 
self-administered questionnaires within the comprehensive 
KORA assessments.20 Information on current medication was 
assessed by asking all study participants to bring original 
packaging of their medications used during the last 7 days 
before the study examination.
Hypertension was defined as blood pressure val-
ues $140/90 mmHg measured during the visit and/or intake 
of antihypertensive medication, given that the participant was 
aware of having hypertension as assessed in the standardized 
interview or questionnaire. Diabetes mellitus was defined as 
having a self-reported physician diagnosis of diabetes and/or 
intake of antidiabetic medication. The presence of an anxiety 
disorder was defined using the Generalized Anxiety Disorder 
Scale-721 in the standardized interview or questionnaire with 
a score of $10 indicating the presence of an anxiety disor-
der. Depression was assessed using the depression module 
of the Brief Patient Health Questionnaire-D (PHQ-D) in 
KORA-F4 (age 41–63 years), whereas in KORA-Age (age 
65–90 years) it was assessed using the Geriatric Depres-
sion Scale-15 (GDS-15) during the standardized interview, 
where participants with a score of $10 were classified as 
being depressive.22 Smoking habits and symptoms of chronic 
bronchitis, defined as cough and sputum on most days dur-
ing 3 or more months per year, were assessed within the 
standardized interview or questionnaire. Furthermore, infor-
mation on the presence of a physician diagnosis of COPD 
or chronic bronchitis was assessed during the standardized 
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Impact of spirometric criteria on the prevalence of COPD
respiratory disease comprised sympathomimetics, anticho-
linergics, xanthines, leukotriene receptor antagonists, and 
corticosteroids.
Serum and ethylenediaminetetraacetic acid (EDTA) 
plasma samples were obtained from all study participants 
and were stored at -80°C until analysis. Levels of high-
sensitivity CRP were measured in serum (KORA-Age) or 
EDTA plasma samples (KORA-F4) using Cardio Phase® 
hsCRP (Siemens, Eschborn, Germany). Serum IL-6 was 
measured using Quantikine HS Elisa (R&D Systems, Inc., 
Minneapolis, MN, USA). IL-6 measurements were available 
only for the KORA-Age cohort.
statistical analysis
Prevalences are expressed as numbers and percentages of 
subjects with the trait. Subject characteristics and spirometric 
indices are expressed as mean (standard deviation). Basic 
study results are presented according to three age groups 
(,65 years/$65 years and ,75 years/$75 years) and 
spirometric results on the basis of FEV
1
/FVC categories. 
As the distributions of the biomarker levels were skewed, 
results were log
10
 transformed before further analysis. For the 
outcome variables of comorbidities, self-reported physician 
diagnosis of COPD/chronic bronchitis, use of lung medica-
tion, chronic bronchitis symptoms, and ever-smoking logistic 
regression models were generated including sex and age as 
factors. The influence of the following dichotomous variables 
was then tested by separately including them into these basic 
models: 1) cases vs healthy subjects by the FR criterion, 
2) cases vs healthy subjects by the LLN criterion, and 3) cases 
by the FR criterion only vs cases by the LLN criterion. All 
LLN-defined COPD cases were included in the respective 
FR-defined group except for one subject in the age group of 





(IL-6) general linear 
models were generated including sex and age as predictors. 
The influence of the dichotomous variables for COPD defini-
tion was then tested analogously. Analyses were performed 
using the commercially available software SAS 9.3 (SAS 
Institute Inc., Cary, NC, USA) and Statgraphics Centurion 
XVII (Statpoint Technologies Inc., Warrenton, VA, USA); 
additional plots were done using SigmaPlot 12.0 (Systat 
Software Inc., San Jose, CA, USA).
Results
In total, 2,256 individuals were included: 1,321 from 
KORA-F4 (618 men and 703 women) and 935 from KORA-
Age (474 men and 461 women). Table 1 summarizes 
descriptive data of our study participants from both cohorts 
separately and combined. All study participants from 
KORA-F4 were younger than 65 years (41–63 years), and 
all participants from KORA-Age were 65 years and older 
(65–90 years).
The prevalence of COPD defined by spirometry without 
bronchodilation according to the FR criterion increased 
with age from ~10% for the age group below 65 years to 
21% for the age group between 65 years and 75 years, and 
finally 26% for individuals in the age group of 75 years and 
older (Table 2), but was predominantly confined to mild 
and moderate stages of COPD. Severe and very severe COPD 
grades were rare in our population-based study (nine cases 
in total) and did not differ between FR and LLN criteria for 
all age groups. The prevalence of COPD on the basis of the 
LLN criterion remained stable below 10% up to an age of 
90 years. The drifting apart with increasing age between 
both COPD definitions, depending on the diagnostic criteria 
used (FR vs LLN), became most prominent at age beyond 
65 years (Figure 1).
As shown in Table 3, the presence of a self-reported 
physician diagnosis of COPD/chronic bronchitis in cases 
of spirometrically defined COPD was generally rather 
low ranging between 14% and 38%. However, it was pre-
dominantly higher for LLN-defined COPD than for the FR 
criterion as was true for the current use of lung medication 
and the presence of chronic bronchitis symptoms. In the 
logistic regression model, this difference between the spiro-
metric criteria was observed for all three aspects (Table 4). 
Regarding ever smoking, differences of cases vs no COPD 
by both criteria were most prominent in the youngest age 
group (Table 3), while no differences between the two COPD 
criteria were observed.
Table 5 shows the odds ratio estimates for the influence 
of COPD according to FR and LLN criteria on disease 
prevalence from the logistic regression models; primary 
prevalences of comorbidities are given in Figure S1A–C. By 
trend, differences between subjects with and without COPD 
were most prominent in males for the LLN criterion for MI, 
cancer, stroke, and anxiety in the middle and oldest age group 
and for GID in the youngest age group. Although a similar 
trend was observed for GID in females in the youngest age 
group, other comorbidities did not show consistent tenden-
cies in women. On the other hand, as shown in Table 5, the 
prevalence of obesity was consistently lower in COPD cases, 
which was independent of the criterion. Beyond this observa-
tion, no firm pattern was observed regarding the prevalence 
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Table 1 General characteristics of the KORA-F4 and KORA-Age study participants with spirometric data
KORA-F416 KORA-Age17 Cohorts combined
Men Women Men Women Men Women
Subjects, N 618 703 474 461 1,092 1,164
Age, years: mean (SD) 51.7 (5.8) 51.6 (5.6) 75.6 (6.3) 75.7 (6.3) 62.1 (13.3) 61.1 (13.2)
Age category N (%)
Age ,65 years 618 (100.0) 703 (100.0) 0 0 618 (56.6) 703 (60.4)
Age 65–74 years 0 0 210 (44.3) 207 (44.9) 210 (19.2) 207 (17.8)
Age $75 years 0 0 264 (55.7) 254 (55.1) 264 (24.2) 254 (21.8)
Height, cm: mean (SD) 177.0 (6.4) 163.3 (6.1) 171.0 (6.9) 157.7 (6.1) 174.4 (7.2) 161.1 (6.7)
Weight, kg: mean (SD) 87.9 (15.4) 71.6 (14.1) 83.1 (12.7) 70.6 (12.0) 85.8 (14.5) 71.2 (13.3)
BMI, kg/m2: mean (sD) 28.0 (4.5) 26.8 (5.2) 28.4 (3.9) 28.4 (4.6) 28.2 (4.2) 27.4 (5.1)
Non-lung diseases, N (%) 365 (59.1) 409 (58.2) 430 (90.7) 414 (89.8) 795 (72.8) 823 (70.7)
Number of non-lung diseases, N: median (IQR) 1 (0–2) 1 (0–1) 2 (1–3) 2 (1–3) 1 (0–2) 1 (0–2)
Smoking status: N (%)
Current 155 (25.1) 151 (21.5) 26 (5.5) 18 (3.9) 181 (16.6) 169 (14.5)
ex 283 (45.8) 255 (36.3) 266 (56.1) 97 (21.0) 549 (50.3) 352 (30.2)
never 180 (29.1) 297 (42.2) 182 (38.4) 346 (75.1) 362 (33.2) 643 (55.2)
Lung function: mean (SD)
FeV1 (l) 3.92 (0.71) 2.84 (0.52) 2.92 (0.69) 2.06 (0.45) 3.48 (0.86) 2.53 (0.62)
FVC (l) 5.07 (0.80) 3.64 (0.62) 3.99 (0.79) 2.73 (0.57) 4.60 (0.96) 3.28 (0.75)
FeV1/FVC 0.77 (0.06) 0.78 (0.06) 0.73 (0.09) 0.76 (0.08) 0.75 (0.08) 0.77 (0.07)
FeV1/FVC category: N (%)
FeV1/FVC $80% 222 (35.9) 295 (42.0) 83 (17.5) 118 (25.6) 305 (27.9) 413 (35.5)
70%# FeV1/FVC ,80% 327 (52.9) 345 (49.1) 261 (55.1) 249 (54.0) 588 (53.8) 594 (51.0)
FeV1/FVC ,70% 69 (11.2) 63 (9.0) 130 (27.4) 94 (20.4) 199 (18.2) 157 (13.5)
FeV1/FVC , lln 45 (7.3) 52 (7.4) 36 (7.6) 20 (4.3) 81 (7.4) 72 (6.2)
glI Z-scores: mean (sD)
FeV1 0.212 (1.142) 0.272 (1.178) 0.335 (1.249) 0.443 (1.108) 0.265 (1.190) 0.340 (1.153)
FVC 0.297 (0.936) 0.401 (0.996) 0.488 (1.071) 0.500 (0.965) 0.380 (1.001) 0.440 (0.985)
FeV1/FVC -0.200 (0.892) -0.305 (0.888) -0.285 (1.014) -0.216 (0.912) -0.235 (0.947) -0.269 (0.898)
Note: lln and Z-scores were calculated according to GLI reference values.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GLI, Global Lungs Initiative; LLN, lower limit of normal; IQR, 
interquartile range.
Table 2 COPD based on FR (FEV1/FVC ,0.7) and LLN (FEV1/FVC , LLN) criteria by age and sex (N, % of group)
Total Male Female
FR LLN FR LLN FR LLN
Age ,65 years
All subjects (N) 1,321 618 703
no COPD 1,189 (90.0) 1,224 (92.7) 549 (88.8) 573 (92.7) 640 (91.0) 651 (92.6)
COPD 132 (10.0) 97 (7.3) 69 (11.2) 45 (7.3) 63 (9.0) 52 (7.4)
Mild (FeV1 $80%) 83 (6.3) 57 (4.3) 42 (6.8) 25 (4.0) 41 (5.8) 32 (4.6)
Moderate–very severe (FeV1 ,80%) 49 (3.7) 40 (3.0) 27 (4.4) 20 (3.2) 22 (3.1) 20 (2.8)
Age 65–74 years
All subjects (N) 417 210 207
no COPD 330 (79.1) 390 (93.5) 162 (77.1) 195 (92.9) 168 (81.2) 195 (94.2)
COPD 87 (20.8) 27 (6.5) 48 (22.9) 15 (7.1) 39 (18.8) 12 (5.8)
Mild (FeV1 $80%) 61 (14.6) 15 (3.6) 32 (15.2) 6 (2.9) 29 (14.0) 9 (4.3)
Moderate–very severe (FeV1 ,80%) 26 (6.2) 12 (2.9) 16 (7.6) 9 (4.3) 10 (4.8) 3 (1.4)
Age $75 years
All subjects (N) 518 264 254
no COPD 381 (73.6) 489 (94.4) 182 (68.9) 243 (92.0) 199 (78.3) 246 (96.9)
COPD 137 (26.4) 29 (5.6) 82 (31.1) 21 (8.0) 55 (21.7) 8 (3.1)
Mild (FeV1 $80%) 89 (17.2) 6 (1.2) 49 (18.6) 4 (1.5) 40 (15.7) 2 (0.8)
Moderate–very severe (FeV1 ,80%) 48 (9.3) 23 (4.4) 33 (12.5) 17 (6.4) 15 (5.9) 6 (2.4)
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Impact of spirometric criteria on the prevalence of COPD
or more comorbidities was lower in subjects with vs without 
COPD defined by the LLN criterion (Table 5).
The estimates for the effect of COPD on levels of CRP 
and IL-6 are presented in Table 6; median CRP and IL-6 
levels are shown in Figure S2A and B. Levels of both bio-
markers slightly increased with age in all participants without 
COPD, but consistent differences between FR- and LLN-
defined COPD were not detectable. Still, both CRP and IL-6 
tended to be higher in cases by both criteria (Table 6).
Discussion
In epidemiology, the definition of COPD disease status is 
frequently based on either spirometric results, often without 
bronchodilation, or questionnaire data of physician diagnosis. 
In this population-based observational study, the impact of 
disease definition by different spirometric criteria (FR vs 
LLN) on COPD prevalence was evident and increased with 
age (Figure 1). The tendency of COPD being possibly over-
diagnosed by the FR criterion becomes more pronounced 
in advanced age, most prominently beyond 65 years in our 
sample. However, neither the prevalence of common comor-
bidities nor levels of the inflammatory biomarkers CRP and 
IL-6 were affected by the selection of the COPD criterion. 
Our results have to be considered in light of the fact that 
in our epidemiological cohort we predominantly observed 
participants with mild-to-moderate airflow obstruction based 
on spirometry without bronchodilation.
Figure 1 Prevalence of spirometrically defined COPD based on FR (light gray) or LLN (dark gray) criterion.
Note: All LLN-defined COPD cases were included in the respective FR-defined group, except for one subject in the age group of 40–44 years.
Abbreviations: FR, fixed ratio; LLN, lower limit of normal.
Table 3 Frequency (%) of self-reported physician diagnosis of 
COPD or chronic bronchitis, current use of lung medication, 
symptoms of chronic bronchitis, and ever smoking in subjects 
classified by FR (FEV1/FVC ,0.7) and LLN (FEV1/FVC , lln) 
criteria
Physician diagnosis 
of COPD or 
chronic bronchitis
Current 









Fr 6.2 2.5 3.2 61.6
lln 6.5 2.9 3.1 62.2
COPD
Fr 26.2 16.7 3.8 84.9
lln 29.2 17.5 5.2 85.6
Age 65–74 years
no COPD
Fr 4.6 3.3 3.9 44.2
lln 5.6 4.6 4.9 45.9
COPD
Fr 13.8 13.8 14.9 56.3
lln 18.5 18.5 25.9 59.3
Age $75 years
no COPD
Fr 6.3 2.9 5.0 36.0
lln 8.8 4.9 6.1 40.1
COPD
Fr 21.9 19.0 14.6 54.7
lln 37.9 44.8 31.0 55.2
Abbreviations: FeV1, forced expiratory volume in 1 second; FR, fixed ratio; FVC, 
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Table 4 Odds ratio estimates (95% CI) for lung-associated parameters by spirometric criterion (FR: FEV1/FVC ,0.7; LLN: 
FeV1/FVC ,lower limit of normal) from adjusted logistic regression models 
Lung-associated 
parameters
FR criterion (COPD vs healthy 
subjects)
LLN criterion (COPD vs 
healthy subjects)
LLN vs FR criterion (LLN-
defined COPD vs LLN-defined 
healthy subjects within FR-
defined COPD subjects)
Odds ratio estimate P-value Odds ratio estimate P-value Odds ratio estimate P-value
Physician diagnosis of COPD or 
chronic bronchitis
4.458 (3.204; 6.204) ,0.001 5.777 (3.901; 8.553) ,0.001 2.57 (1.425; 4.636) 0.002
Current lung medication 6.913 (4.605; 10.378) ,0.001 8.280 (5.292; 12.955) ,0.001 2.560 (1.349; 4.860) 0.004
Symptoms of chronic bronchitis 2.681 (1.749; 4.109) ,0.001 3.916 (2.340; 6.554) ,0.001 3.422 (1.589; 7.370) 0.002
ever smoked 2.230 (1.724; 2.886) ,0.001 2.463 (1.668; 3.637) ,0.001 1.145 (0.653; 2.008) 0.636
Note: results with P,0.05 are indicated in bold.
Abbreviations: CRP, C-reactive protein; FR, fixed ratio; IL-6, interleukin-6; LLN, lower limit of normal.
Table 5 Odds ratio estimates (95% CI) for comorbidities by spirometric criterion (FR: FEV1/FVC ,0.7; LLN: FEV1/FVC , lln) from 
adjusted logistic regression models
Comorbidities FR criterion (COPD vs healthy 
subjects)
LLN criterion (COPD vs  
healthy subjects)
LLN vs FR criterion (LLN-
defined COPD vs LLN-defined 
healthy subjects within FR-
defined COPD subjects)
Odds ratio estimate P-value Odds ratio estimate P-value Odds ratio estimate P-value
hypertension 1.017 (0.779; 1.328) 0.901 0.836 (0.570; 1.224) 0.356 0.617 (0.365; 1.042) 0.071
MI 1.036 (0.654; 1.640) 0.881 1.457 (0.748; 2.839) 0.268 1.719 (0.716; 4.127) 0.225
stroke 0.779 (0.436; 1.390) 0.397 1.143 (0.479; 2.728) 0.763 1.247 (0.404; 3.849) 0.701
Cancer 0.905 (0.609; 1.345) 0.621 1.183 (0.661; 2.118) 0.571 1.604 (0.732; 3.517) 0.238
Diabetes 0.767 (0.518; 1.137) 0.187 0.492 (0.224; 1.081) 0.077 0.547 (0.220; 1.357) 0.193
Obesity 0.671 (0.511; 0.882) 0.004 0.606 (0.400; 0.920) 0.019 0.756 (0.423; 1.350) 0.344
arthritis 0.864 (0.595; 1.255) 0.442 0.942 (0.531; 1.674) 0.839 1.022 (0.473; 2.208) 0.956
anxiety 1.033 (0.666; 1.602) 0.885 0.886 (0.456; 1.722) 0.722 0.907 (0.356; 2.312) 0.838
Depression 1.203 (0.482; 3.000) 0.692 0.922 (0.218; 3.897) 0.912 0.475 (0.064; 3.532) 0.467
gID 1.053 (0.729; 1.521) 0.782 1.114 (0.667; 1.859) 0.680 0.834 (0.381; 1.824) 0.650
$2 comorbidities 0.791 (0.612; 1.022) 0.073 0.650 (0.440; 0.960) 0.030 0.689 (0.410; 1.159) 0.161
Note: results with P,0.05 are indicated in bold.
Abbreviations: CRP, C-reactive protein; FEV1, forced expiratory volume in 1 second; FR, fixed ratio; FVC, forced vital capacity; GID, gastrointestinal disease; IL-6, 
interleukin-6; LLN, lower limit of normal; MI, myocardial infarction.
The prevalence of respiratory obstruction we observed 
for both spirometric criteria compared well with recent 
population-based analyses that were performed in a similar 
fashion. For example, in a large Canadian sample, an overall 
obstruction prevalence of 17% by the FR criterion has been 
reported for the age range of 40–93 years,23 Turkeshi et al24 
found an FR-based prevalence of 27% in a Belgian sample of 
very old adults aged 80 years or older. However, the preva-
lence of ~7% we found for LLN was slightly lower than the 
range of 9%–11% reported in these studies.
Unexpectedly, study participants with spirometrically 
defined COPD generally did not suffer from more comor-
bidities than participants of the same age without COPD 
irrespective of the applied spirometric criterion. Although 
a tendency toward higher prevalences of MI, cancer, stroke, 
and anxiety was observed in participants with LLN-defined 
COPD compared with participants without LLN-defined 
COPD, there was no distinct difference after taking account 
of the sex and age in logistic regression models. On the 
contrary, we found a lower prevalence of obesity in COPD 
subjects for both criteria, which might be explained by a 
higher fraction of smokers among these subjects.25 None 
of the other comorbidities evaluated were more prevalent 
among COPD participants, which is in contrast to findings 
from other studies.26–28 The lack of a difference may partly 
be explained by the fact that our study was conducted in 
the general population with predominantly mild cases as 
opposed to a clinical setting with more severe stages of 
COPD. The prevalences we found in spirometrically defined 
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Impact of spirometric criteria on the prevalence of COPD
Table 6 Parameter estimates (95% CI) for CRP and IL-6 levels from general linear models by FR and LLN criterion
Biomarkers FR criterion (COPD vs healthy 
subjects)
LLN criterion (COPD vs 
healthy subjects)
LLN vs FR criterion (LLN-
defined COPD vs LLN-defined 









CrP 1.154 (1.016; 1.311) 0.027 1.121 (0.934; 1.346) 0.220 0.989 (0.758; 1.292) 0.937
Il-6 1.036 (0.935; 1.148) 0.498 1.178 (0.979; 1.418) 0.083 1.163 (0.937; 1.443) 0.171
Notes: Parameter estimates (95% CI) for CRP and IL-6 have been back-transformed from the model based on log10-transformed biomarker values and thus have to be 
regarded as factors on the respective biomarker levels. Results with P,0.05 are indicated in bold.
Abbreviations: CRP, C-reactive protein; FR, fixed ratio; IL-6, interleukin-6; LLN, lower limit of normal.
with findings described by Divo et al29 in a recent analysis of 
COPD patients based on the BODE registry, when consider-
ing comparable age groups. However, our prevalences for 
hypertension were markedly higher, while those for depres-
sion were lower, which might be attributed to differences 
in the assessment of those comorbidities. Furthermore, the 
COPD cases as defined in our study were predominantly 
mild and mostly not yet confirmed by a physician, as indi-
cated by the rather poor overlap with physician diagnoses, 
(Table 3) suggesting early undiagnosed cases to a large 
degree. Moreover, the increased fraction of ever smokers 
especially in the youngest age group points to the fact that 
this factor is of importance predominantly in COPD at 
comparably young age. It might be speculated that possible 
concomitant systemic impairments in these cases are in a 
comparably early stage and thus are not or not yet diagnosed 
by a physician. Alternatively, a limitation in airway function 
may precede the affections of other organs that are later 
described as comorbidities in COPD. The exploration of a 
possible sequence in this regard, however, would require a 
longitudinal evaluation, which was beyond the scope of the 
current cross-sectional study.
In recent years, systemic inflammation has come into the 
focus of COPD research, and increased serum levels of IL-6 
and CRP in COPD participants have been reported.30 Although 
we found a tendency toward elevated values for both markers 
in COPD participants, the overall effect was comparatively 
small. The lack of findings, particularly in the aged, may, in 
our case, be partly explained by harvesting, where subjects in 
poor health did not survive or did not participate in the study as 
they were unable to get into the study center. A recent study by 
Silva et al31 did not find markedly elevated CRP in nonsmok-
ing COPD patients compared to a control group indicating the 
possible impact of active smoking on this parameter. However, 
the tendency toward higher IL-6 levels in LLN-defined COPD 
cases in older age for males suggests that this criterion may be 
diagnostically more specific in identifying participants with 
(early stage) systemic inflammation than the FR and needs 
confirmation in longitudinal settings.
Consequently, these findings indicate that the application 
of the LLN criterion in epidemiological or clinical settings 
will result in an identification of subjects with more concomi-
tant typical characteristics of COPD, eg, chronic bronchitis 
symptoms, and a higher probability of a physician diagnosis 
of COPD compared to FR (Table 4). However, since no con-
sistent differences in comorbidity prevalences or biomarker 
levels were observed, the preference of one criterion over 
the other in this regard could not be derived from our study. 
Beyond the FEV
1
/FVC ratio, the use of more advanced lung 
function measurements such as body plethysmography32 
could provide a refined characterization of patient subgroups 
with a higher number or specific patterns of comorbidities.
The limitation of the current study might be the fact 
that the definition of COPD cases here, as a rather common 
epidemiological approach, was solely based on spirometric 
results as opposed to a usually more comprehensive approach 
in clinical practice including anamnesis, symptoms, risk fac-
tors, and individual clinical history. However, the restriction 
to different interpretations of a spirometric measure allowed 
us to specifically focus on the impact of this particular com-
ponent of the diagnostic sequence in predominantly early, 
often undiagnosed cases of airway obstruction according to 
our research question. A clear strength of our study is the 
inclusion of participants from the general population up 
to an advanced age of 90 years, an age group that is often 
underrepresented in COPD studies.
Conclusion
In a population-based sample of adults in middle and 
advanced age, we found that the prevalence of spirometrically 
defined COPD was higher when using the FR criterion as 
opposed to LLN and this difference increased with increasing 
age. However, for the predominantly mild cases observed in 
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spirometric criteria on the prevalence of comorbidities and 
on common inflammatory biomarker levels.
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Impact of spirometric criteria on the prevalence of COPD
Figure S1 (A–C) Prevalence of comorbidities in subjects without COPD (light grey) or with COPD (dark grey) by FR (FEV1/FVC ,0.7; solid color) and LLN (FEV1/FVC ,lower 
limit of normal; hatched) criterion (percentages).
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Impact of spirometric criteria on the prevalence of COPD
Figure S2  (A–B) Levels of CRP and IL-6 in subjects without COPD (light grey) and COPD cases (dark grey) based on FR (FEV1/FVC ,0.7; solid color) or LLN 
(FeV1/FVC ,lower limit of normal; hatched) criterion (number of subjects per group are given in brackets).
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